PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 23675643-5 2013 Furthermore, the combination of equol (100 muM) and 4-OHT (10 muM) induced apoptosis more effectively than each compound alone. Equol 32-37 latexin Homo sapiens 43-46 23675643-5 2013 Furthermore, the combination of equol (100 muM) and 4-OHT (10 muM) induced apoptosis more effectively than each compound alone. Equol 32-37 latexin Homo sapiens 62-65 22213181-7 2012 In line with E2, mRNA expression of Nefm and Zdhhc-2 was down-regulated following 8-PN, GEN, DAI, EQ and naringenin treatment. Equol 98-100 neurofilament medium chain Rattus norvegicus 36-40 23482760-8 2013 RESULTS: Equol enhanced TRAIL-induced apoptosis through activation of caspase-3, -8, -9, and cleavage of BID. Equol 9-14 TNF superfamily member 10 Homo sapiens 24-29 23482760-8 2013 RESULTS: Equol enhanced TRAIL-induced apoptosis through activation of caspase-3, -8, -9, and cleavage of BID. Equol 9-14 caspase 3 Homo sapiens 70-87 23482760-8 2013 RESULTS: Equol enhanced TRAIL-induced apoptosis through activation of caspase-3, -8, -9, and cleavage of BID. Equol 9-14 BH3 interacting domain death agonist Homo sapiens 105-108 23482760-10 2013 CONCLUSION: Equol enhances TRAIL-induced apoptosis of HeLa cells through a death receptor-mediated caspase pathway. Equol 12-17 TNF superfamily member 10 Homo sapiens 27-32 23482760-10 2013 CONCLUSION: Equol enhances TRAIL-induced apoptosis of HeLa cells through a death receptor-mediated caspase pathway. Equol 12-17 caspase 8 Homo sapiens 99-106 23220561-9 2013 EQ displayed typical ER-agonistic actions as shown by the significant increases in ERalpha-, TERP-1/-2 mRNA expressions and serum PRL levels along with the significant reduction in serum LH levels, whereas FLUT exerted opposite effects on gonadotropin secretion and expression. Equol 0-2 estrogen receptor 1 Rattus norvegicus 83-90 23220561-9 2013 EQ displayed typical ER-agonistic actions as shown by the significant increases in ERalpha-, TERP-1/-2 mRNA expressions and serum PRL levels along with the significant reduction in serum LH levels, whereas FLUT exerted opposite effects on gonadotropin secretion and expression. Equol 0-2 prolactin Rattus norvegicus 130-133 23088310-4 2012 Using L-buthionine (S,R)-sulfoximine (BSO) to induce oxidative stress in human FRDA fibroblasts, we determine the potency and efficacy of the soy-derived ERbeta agonist S-equol and its ERalpha-preferring enantiomer, R-equol in vitro on cell viability and ROS accumulation. Equol 169-176 estrogen receptor 1 Homo sapiens 154-160 22213181-7 2012 In line with E2, mRNA expression of Nefm and Zdhhc-2 was down-regulated following 8-PN, GEN, DAI, EQ and naringenin treatment. Equol 98-100 zinc finger DHHC-type palmitoyltransferase 2 Rattus norvegicus 45-52 22683650-4 2012 Genistein and (S)-Equol, a metabolite of daidzein, induced rat SHARP-2 gene expression in H4IIE rat hepatoma cells. Equol 14-23 basic helix-loop-helix family, member e40 Rattus norvegicus 63-70 22683650-6 2012 When a dominant negative form of atypical PKC lambda (aPKClambda) was expressed, the induction of SHARP-2 mRNA level by (S)-Equol was inhibited. Equol 120-129 basic helix-loop-helix family, member e40 Rattus norvegicus 98-105 22449546-1 2012 S-equol is a selective estrogen receptor beta (ERbeta) agonist which is produced in certain individuals after ingestion of its precursor daidzein, an isoflavone present in soy. Equol 0-7 estrogen receptor 2 Rattus norvegicus 23-45 22788991-4 2012 Curcumin, genistein, epigallocatechin-gallate, equol, and resveratrol efficiently killed both androgen-receptor positive (22Rv1) and negative cell lines (PC-3, DU145) in combination with adenoviral mutants. Equol 47-52 androgen receptor Homo sapiens 94-111 22871233-3 2012 We examined the effects of isoflavones, genistein, daidzein, and equol, on the expression of the high-affinity immunoglobulin E (IgE) receptor, FcepsilonRI, which plays a central role in IgE-mediated allergic response. Equol 65-70 Fc epsilon receptor Ia Homo sapiens 144-155 22449546-1 2012 S-equol is a selective estrogen receptor beta (ERbeta) agonist which is produced in certain individuals after ingestion of its precursor daidzein, an isoflavone present in soy. Equol 0-7 estrogen receptor 2 Rattus norvegicus 47-53 21667019-5 2011 Equol administration at a higher dose effectively suppressed tumor formation and PCNA over-expression. Equol 0-5 proliferating cell nuclear antigen Rattus norvegicus 81-85 21945492-7 2011 Isoflavones (formononetin, daidzein, equol, biochanin A, genistein) were found to differentially affect the expression of CD86, a costimulatory molecule, on lipopolysaccharide (LPS)-stimulated DCs. Equol 37-42 CD86 molecule Homo sapiens 122-126 22377671-8 2012 These data are consistent with the vasorelaxation activity of equol and phenoxodiol deriving at least in part by inhibition of the RhoA/Rho-kinase pathway, and along with the limited estrogen receptor affinity supports a role for equol and phenoxodiol as useful agents for maintaining cardiovascular function with limited estrogenic effects. Equol 62-67 ras homolog family member A Rattus norvegicus 131-135 22179235-7 2012 Analysis of E. coli strains containing an expression vector incorporating one of the orf-1, -2, or -3 genes revealed that (i) the protein encoded by orf-1 was involved in the conversion of cis/trans-tetrahydrodaidzein (cis/trans-THD) to equol, (ii) the protein encoded by orf-2 was involved in the conversion of DHD to cis/trans-THD, and (iii) the protein encoded by orf-3 was involved in the conversion of daidzein to DHD. Equol 237-242 hypothetical protein Escherichia coli 149-154 21667019-10 2011 Although equol did not affect the ratio of oxidized to reduced glutathione, it activated the glutathione peroxidase and glutathione reductase enzymes, and this effect was significant at a dose of 25 mg equol/kg body weight. Equol 9-14 glutathione-disulfide reductase Rattus norvegicus 120-141 21300668-1 2011 We reported previously that dietary isoflavones modulate arterial blood pressure in vivo and that the daidzein metabolite equol rapidly activates endothelial NO synthase (eNOS) via Akt and extracellular signal-regulated kinase 1/2-dependent signaling. Equol 122-127 AKT serine/threonine kinase 1 Homo sapiens 181-184 21861338-8 2011 CONCLUSION: R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha. Equol 31-39 chromobox 8 Homo sapiens 75-78 21861338-8 2011 CONCLUSION: R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha. Equol 31-39 chromobox 8 Homo sapiens 141-144 21861338-8 2011 CONCLUSION: R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha. Equol 31-39 estrogen receptor 1 Homo sapiens 210-233 21300668-1 2011 We reported previously that dietary isoflavones modulate arterial blood pressure in vivo and that the daidzein metabolite equol rapidly activates endothelial NO synthase (eNOS) via Akt and extracellular signal-regulated kinase 1/2-dependent signaling. Equol 122-127 mitogen-activated protein kinase 3 Homo sapiens 189-228 21300668-3 2011 Scavengers of superoxide (superoxide dismutase and manganese [III] tetrakis[1-methyl-4-pyridyl]porphyrin) abrogated equol stimulated Akt and eNOS phosphorylation, and the mitochondrial complex I inhibitor rotenone inhibited Akt, extracellular signal-regulated kinase 1/2, and eNOS phosphorylation, as well as NO-mediated increases in intracellular cGMP. Equol 116-121 AKT serine/threonine kinase 1 Homo sapiens 133-136 21300668-3 2011 Scavengers of superoxide (superoxide dismutase and manganese [III] tetrakis[1-methyl-4-pyridyl]porphyrin) abrogated equol stimulated Akt and eNOS phosphorylation, and the mitochondrial complex I inhibitor rotenone inhibited Akt, extracellular signal-regulated kinase 1/2, and eNOS phosphorylation, as well as NO-mediated increases in intracellular cGMP. Equol 116-121 AKT serine/threonine kinase 1 Homo sapiens 224-227 21300668-3 2011 Scavengers of superoxide (superoxide dismutase and manganese [III] tetrakis[1-methyl-4-pyridyl]porphyrin) abrogated equol stimulated Akt and eNOS phosphorylation, and the mitochondrial complex I inhibitor rotenone inhibited Akt, extracellular signal-regulated kinase 1/2, and eNOS phosphorylation, as well as NO-mediated increases in intracellular cGMP. Equol 116-121 mitogen-activated protein kinase 3 Homo sapiens 229-270 21300668-5 2011 Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Equol 129-134 G protein-coupled estrogen receptor 1 Homo sapiens 57-62 21300668-5 2011 Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Equol 129-134 epidermal growth factor receptor Homo sapiens 63-95 21300668-5 2011 Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Equol 129-134 mitogen-activated protein kinase 3 Homo sapiens 157-198 21300668-5 2011 Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Equol 129-134 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 203-208 21300668-5 2011 Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Equol 129-134 AKT serine/threonine kinase 1 Homo sapiens 210-213 21056663-8 2011 Equol induced a conformational change in the ERRgamma ligand-binding domain. Equol 0-5 estrogen related receptor gamma Homo sapiens 45-53 21232127-16 2011 Equol administration: reduces PSA levels from LNCap cells under 5alpha-DHT stimulation, decreases rat prostate size, decreases serum 5alpha-DHT levels and androgen hormone action, while not altering other circulating sex steroids or LH levels. Equol 0-5 kallikrein related peptidase 3 Homo sapiens 30-33 21056663-10 2011 Finally, equol enhanced the growth inhibitory effect of ERRgamma on the prostate cancer PC-3 cells. Equol 9-14 estrogen related receptor gamma Homo sapiens 56-64 20110282-2 2010 S-(-)equol, a ligand for ERbeta, is an intestinally derived metabolite formed by many humans and by rodents consuming diets containing soy isoflavones. Equol 0-10 estrogen receptor 2 Homo sapiens 25-31 20453869-0 2010 Effects of genistein and equol on human and rat testicular 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities. Equol 25-30 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Rattus norvegicus 59-93 20453869-0 2010 Effects of genistein and equol on human and rat testicular 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities. Equol 25-30 hydroxysteroid (17-beta) dehydrogenase 3 Rattus norvegicus 98-135 20453869-1 2010 The objective of the present study was to investigate the effects of genistein and equol on 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 17beta-hydroxysteroid dehydrogenase 3 (17beta-HSD3) in human and rat testis microsomes. Equol 83-88 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Homo sapiens 92-126 20453869-1 2010 The objective of the present study was to investigate the effects of genistein and equol on 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 17beta-hydroxysteroid dehydrogenase 3 (17beta-HSD3) in human and rat testis microsomes. Equol 83-88 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Homo sapiens 128-137 20453869-1 2010 The objective of the present study was to investigate the effects of genistein and equol on 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 17beta-hydroxysteroid dehydrogenase 3 (17beta-HSD3) in human and rat testis microsomes. Equol 83-88 hydroxysteroid 17-beta dehydrogenase 3 Homo sapiens 143-180 20505019-1 2010 Equol, a product of intestinal metabolism of daidzein, is chemically similar to estrogen (without the lipophilic moiety) and has higher estrogen receptor-beta binding affinity than its parent precursor. Equol 0-5 estrogen receptor 2 Homo sapiens 136-158 19776178-1 2009 The soy isoflavone metabolite, S-(-)equol, has selective affinity for estrogen receptor (ER)beta and also antagonizes in vivo the action of dihydrotestosterone. Equol 31-41 estrogen receptor 2 Homo sapiens 70-96 19427779-0 2010 Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells. Equol 94-99 mitogen-activated protein kinase 1 Homo sapiens 22-63 19427779-1 2010 The aim of this study was to determine whether the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway is involved in genistein- and equol-induced cell proliferation and estrogen receptor (ER) alpha transactivation. Equol 140-145 mitogen-activated protein kinase 1 Homo sapiens 51-92 19427779-1 2010 The aim of this study was to determine whether the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway is involved in genistein- and equol-induced cell proliferation and estrogen receptor (ER) alpha transactivation. Equol 140-145 mitogen-activated protein kinase 3 Homo sapiens 94-100 19427779-1 2010 The aim of this study was to determine whether the extracellular-signal-regulated kinase 1/2 (ERK1/2) pathway is involved in genistein- and equol-induced cell proliferation and estrogen receptor (ER) alpha transactivation. Equol 140-145 estrogen receptor 1 Homo sapiens 177-205 19427779-3 2010 Genistein- and equol-induced cell proliferation and S-phase entry were blocked by the ERalpha antagonists 4-hydroxytamoxifen and ICI 182,780 and by the mitogen-activated protein kinase 1/2 inhibitor U0126. Equol 15-20 estrogen receptor 1 Homo sapiens 86-93 19427779-3 2010 Genistein- and equol-induced cell proliferation and S-phase entry were blocked by the ERalpha antagonists 4-hydroxytamoxifen and ICI 182,780 and by the mitogen-activated protein kinase 1/2 inhibitor U0126. Equol 15-20 mitogen-activated protein kinase 1 Homo sapiens 152-186 19427779-6 2010 Inhibition of ERK1/2 phosphorylation by U0126 led to complete suppression of genistein- and equol-induced estrogen response element reporter activity and to suppression of the estrogen-responsive gene pS2. Equol 92-97 mitogen-activated protein kinase 3 Homo sapiens 14-20 19427779-9 2010 In conclusion, genistein and equol elicit a delayed activation of ERK1/2, and this activation appears to be involved in the proliferation of breast cancer cells and estrogen-dependent transcriptional activation. Equol 29-34 mitogen-activated protein kinase 3 Homo sapiens 66-72 20354350-6 2010 Strong induction of OVA-specific IgE production by equol was also observed in ovariectomized BALB/c mice, suggesting that the immunomodulatory effect of equol is not affected by endogenous estrogen. Equol 51-56 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 20-23 19304836-7 2009 Finally, the intermediate (3R,4S)-THD was reduced into (3S)-equol by the whole cell, indicating the inversion of stereochemistry at C-3 during the reduction. Equol 55-65 complement C3 Homo sapiens 132-135 19710188-2 2009 S-(-)equol, the naturally occurring enantiomer produced by 20-30% of adults consuming soy foods, has selective affinity for estrogen receptor-beta, whereas both enantiomers modulate androgen action. Equol 0-10 estrogen receptor 2 Homo sapiens 124-146 19297428-3 2009 We investigated the ability of the isoflavones genistein, daidzein, and the daidzein metabolite equol to activate human and mouse PXR in vitro using cell-based transient transfection studies and primary hepatocytes and in vivo in a mouse model. Equol 96-101 nuclear receptor subfamily 1, group I, member 2 Mus musculus 130-133 19297428-10 2009 The results presented herein demonstrate that there is a species-specific difference in the activation of PXR by isoflavones and equol. Equol 129-134 nuclear receptor subfamily 1 group I member 2 Homo sapiens 106-109 18973749-0 2009 Equol induces apoptosis through cytochrome c-mediated caspases cascade in human breast cancer MDA-MB-453 cells. Equol 0-5 cytochrome c, somatic Homo sapiens 32-44 19323753-5 2009 Although equol increased the glutathione peroxidase (GSH-px) activity in mice treated with equol for 1 wk, long-term administration of equol (7 wk) caused a decrease in the ratio of reduced/oxidized glutathione (GSH/GSSG) and the activities of GSH-px and glutathione reductase (GR). Equol 9-14 glutathione reductase Mus musculus 255-276 19323753-5 2009 Although equol increased the glutathione peroxidase (GSH-px) activity in mice treated with equol for 1 wk, long-term administration of equol (7 wk) caused a decrease in the ratio of reduced/oxidized glutathione (GSH/GSSG) and the activities of GSH-px and glutathione reductase (GR). Equol 9-14 glutathione reductase Mus musculus 278-280 18786699-0 2009 Equol is more active than soy isoflavone itself to compete for binding to thromboxane A(2) receptor in human platelets. Equol 0-5 thromboxane A2 receptor Homo sapiens 74-99 18786699-12 2009 CONCLUSIONS: The aglycone isoflavones from soy, and particularly equol, have been found to have biological effects attributable to thromboxane A(2) receptor antagonism. Equol 65-70 thromboxane A2 receptor Homo sapiens 131-156 18973749-0 2009 Equol induces apoptosis through cytochrome c-mediated caspases cascade in human breast cancer MDA-MB-453 cells. Equol 0-5 caspase 8 Homo sapiens 54-62 21479403-7 2008 The expression of Bax and cytochrome c, downstream targets of p53, was markedly increased by treatment with higher concentrations of equol. Equol 133-138 BCL2 associated X, apoptosis regulator Homo sapiens 18-21 21479403-7 2008 The expression of Bax and cytochrome c, downstream targets of p53, was markedly increased by treatment with higher concentrations of equol. Equol 133-138 cytochrome c, somatic Homo sapiens 26-38 21479403-7 2008 The expression of Bax and cytochrome c, downstream targets of p53, was markedly increased by treatment with higher concentrations of equol. Equol 133-138 tumor protein p53 Homo sapiens 62-65 21479403-8 2008 Equol-induced cell cycle arrest and apoptosis apparently involves a p53-dependent pathway in different types of breast cancer cells. Equol 0-5 tumor protein p53 Homo sapiens 68-71 17724030-9 2007 Equol dose-dependently inhibited neoplastic transformation of JB6 P+ cells induced by epidermal growth factor or H-Ras. Equol 0-5 HRas proto-oncogene, GTPase Homo sapiens 113-118 17845735-8 2008 PMN homotypic aggregates, stimulated by fMLP, were significantly reduced (24 (sem 12) and 51 (sem 14) % of control) by 100 microm genistein and equol. Equol 144-149 formyl peptide receptor 1 Homo sapiens 40-44 18203900-8 2008 In an in vitro LPS-induced inflammation model, soy isoflavones (genistein, daidzein, and equol alone or in combination) dose dependently inhibited LPS-induced MCP-1 secretion by macrophages, suggesting a role for soy isoflavones for the protective in vivo effects. Equol 89-94 chemokine (C-C motif) ligand 2 Mus musculus 159-164 16108819-4 2005 In this study we investigated whether formononetin, a phyto-oestrogen, and its metabolites, daidzein and equol, affect production of interleukin-4 (IL-4), a pro-inflammatory cytokine closely associated with allergic immune response, in primary CD4+ T cells and EL4 T lymphoma cells. Equol 105-110 interleukin 4 Mus musculus 133-146 17032659-7 2007 Within the SPI+ group, higher concentrations of serum equol (but not daidzein or genistein) corresponded to significantly lower serum E(1), mammary gland epithelial area and uterine weight (P < 0.01 for all). Equol 54-59 chromogranin A Homo sapiens 11-14 17321472-0 2007 Equol inhibits nitric oxide production and inducible nitric oxide synthase gene expression through down-regulating the activation of Akt. Equol 0-5 nitric oxide synthase 2, inducible Mus musculus 43-74 17321472-0 2007 Equol inhibits nitric oxide production and inducible nitric oxide synthase gene expression through down-regulating the activation of Akt. Equol 0-5 thymoma viral proto-oncogene 1 Mus musculus 133-136 16840783-6 2006 Our findings provide the first evidence that nutritionally relevant plasma concentrations of equol (and other soy protein isoflavones) rapidly stimulate phosphorylation of ERK1/2 and phosphatidylinositol 3-kinase/Akt, leading to the activation of NOS and increased NO production at resting cytosolic Ca2+ levels. Equol 93-98 mitogen-activated protein kinase 3 Homo sapiens 172-178 16840783-6 2006 Our findings provide the first evidence that nutritionally relevant plasma concentrations of equol (and other soy protein isoflavones) rapidly stimulate phosphorylation of ERK1/2 and phosphatidylinositol 3-kinase/Akt, leading to the activation of NOS and increased NO production at resting cytosolic Ca2+ levels. Equol 93-98 AKT serine/threonine kinase 1 Homo sapiens 213-216 16884174-1 2006 The soy isoflavones genistein and daidzein, as well as the daidzein metabolite equol, have structural similarities to mammalian estrogens and bind with varying affinity to both known subtypes of the estrogen receptor. Equol 79-84 estrogen receptor 1 Homo sapiens 199-216 17724030-0 2007 Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. Equol 0-5 midkine Mus musculus 113-116 17724030-0 2007 Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. Equol 0-5 Eph receptor B2 Mus musculus 117-120 17724030-4 2007 Here we report that equol inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced neoplastic transformation of JB6 P+ mouse epidermal cells by targeting the MEK/ERK/p90RSK/activator protein-1 signaling pathway. Equol 20-25 midkine Mus musculus 161-164 17724030-4 2007 Here we report that equol inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced neoplastic transformation of JB6 P+ mouse epidermal cells by targeting the MEK/ERK/p90RSK/activator protein-1 signaling pathway. Equol 20-25 Eph receptor B2 Mus musculus 165-168 17156992-3 2007 The present study examined the effects of four soy isoflavones (genistein, daidzein, glycitein and equol) on extracellularsignal-regulated kinase (ERK1/2) activity in a nontumorigenic prostate epithelial cell line (RWPE-1). Equol 99-104 mitogen-activated protein kinase 3 Homo sapiens 147-153 16870006-4 2006 Genistein, daidzein and equol were found to inhibit COX-2 expression induced by phorbol 12-myristate 13-acetate (PMA). Equol 24-29 prostaglandin-endoperoxide synthase 2 Homo sapiens 52-57 16870006-7 2006 The reporter assay indicated that the transactivation of the hCOX-2 promoter was induced by PMA, and activity was inhibited with the co-administration of genistein, daidzein or equol. Equol 177-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-67 16513288-17 2006 S-equol, a bacterial metabolite of daidzein, has an affinity for ERbeta nearly as high as that of genistein; whether this compound contributes meaningfully to the physiological efficacy of soy isoflavones in some individuals is still unclear. Equol 0-7 estrogen receptor 2 Homo sapiens 65-71 16108819-4 2005 In this study we investigated whether formononetin, a phyto-oestrogen, and its metabolites, daidzein and equol, affect production of interleukin-4 (IL-4), a pro-inflammatory cytokine closely associated with allergic immune response, in primary CD4+ T cells and EL4 T lymphoma cells. Equol 105-110 interleukin 4 Mus musculus 148-152 16108819-6 2005 Formononetin, daidzein and equol also enhanced IL-4 gene promoter activity in EL4 cells transiently transfected with IL-4 gene promoter constructs, but this effect was impaired in EL4 cells transfected with an IL-4 promoter construct deleted of P4 site carrying nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) binding sites. Equol 27-32 interleukin 4 Mus musculus 47-51 16108819-6 2005 Formononetin, daidzein and equol also enhanced IL-4 gene promoter activity in EL4 cells transiently transfected with IL-4 gene promoter constructs, but this effect was impaired in EL4 cells transfected with an IL-4 promoter construct deleted of P4 site carrying nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) binding sites. Equol 27-32 interleukin 4 Mus musculus 117-121 16108819-6 2005 Formononetin, daidzein and equol also enhanced IL-4 gene promoter activity in EL4 cells transiently transfected with IL-4 gene promoter constructs, but this effect was impaired in EL4 cells transfected with an IL-4 promoter construct deleted of P4 site carrying nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) binding sites. Equol 27-32 interleukin 4 Mus musculus 117-121 16108819-6 2005 Formononetin, daidzein and equol also enhanced IL-4 gene promoter activity in EL4 cells transiently transfected with IL-4 gene promoter constructs, but this effect was impaired in EL4 cells transfected with an IL-4 promoter construct deleted of P4 site carrying nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) binding sites. Equol 27-32 jun proto-oncogene Mus musculus 310-329 16108819-6 2005 Formononetin, daidzein and equol also enhanced IL-4 gene promoter activity in EL4 cells transiently transfected with IL-4 gene promoter constructs, but this effect was impaired in EL4 cells transfected with an IL-4 promoter construct deleted of P4 site carrying nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) binding sites. Equol 27-32 jun proto-oncogene Mus musculus 331-335 15883431-0 2005 S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Equol 0-7 estrogen receptor 2 Homo sapiens 29-51 15883431-9 2005 CONCLUSIONS: Humans have acquired an ability to exclusively synthesize S-equol from the precursor soy isoflavone daidzein, and it is significant that, unlike R-equol, this enantiomer has a relatively high affinity for estrogen receptor beta. Equol 71-78 estrogen receptor 2 Homo sapiens 218-240 15323582-6 2005 In a short-term study, equol dose dependently inhibited the SSUV induction of the tumor promotion biomarker enzyme, ornithine decarboxylase, in the skin, suggesting the anticarcinogenic activity of equol may be attributed to its inhibition of the tumor promotion phase of carcinogenesis. Equol 23-28 ornithine decarboxylase, structural 1 Mus musculus 116-139 15151933-12 2004 In conclusion, equol is a weak estrogen with modest effects on endpoints regulated by estrogen receptor alpha when present at serum levels seen in rodents fed soy-based diets, but quantities present in humans may not be sufficient to induce estrogenic effects, although additive effects of equol with other phytoestrogens may occur. Equol 15-20 estrogen receptor 1 Homo sapiens 86-109 15018930-6 2004 In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29). Equol 20-26 estrogen receptor 2 Homo sapiens 73-79 15047177-6 2004 Equol, genistein, AglyMax, and daidzein all markedly stimulated ERbeta-mediated histone acetylation. Equol 0-5 estrogen receptor 2 Homo sapiens 64-70 14681200-6 2004 Equol does not bind the prostatic androgen receptor, and has a modest affinity for recombinant estrogen receptor (ER) beta, and no affinity for ERalpha. Equol 0-5 estrogen receptor 2 Rattus norvegicus 95-122 14681200-8 2004 Therefore, equol can bind circulating DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. Equol 11-16 androgen receptor Rattus norvegicus 68-85 15018930-6 2004 In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29). Equol 20-26 estrogen receptor 2 Homo sapiens 86-92 15018930-6 2004 In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29). Equol 20-26 estrogen receptor 2 Homo sapiens 86-92 15018930-6 2004 In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29). Equol 20-26 estrogen receptor 1 Homo sapiens 260-267 15018930-6 2004 In binding assays, S-equol has a high binding affinity, preferential for ERbeta (K(i)[ERbeta]=16 nM; beta/alpha=13 fold), that is comparable to that of genistein (K(i)[ERbeta]=6.7 nM; beta/alpha=16), whereas R-equol binds more weakly and with a preference for ERalpha (K(i)[ERalpha]=50 nM; beta/alpha=0.29). Equol 20-26 estrogen receptor 1 Homo sapiens 274-281 11187733-6 2000 Equol induces transcription most strongly both with hER beta and hER alpha. Equol 0-5 estrogen receptor 2 Homo sapiens 52-74 14664520-10 2003 The endogenous hormone 17beta-estradiol as well as coumestrol and daidzein metabolite equol activate the binding of ERbeta to ERE only slightly more effectively than the binding of ERalpha to ERE. Equol 86-91 estrogen receptor 2 Homo sapiens 116-122 14664520-10 2003 The endogenous hormone 17beta-estradiol as well as coumestrol and daidzein metabolite equol activate the binding of ERbeta to ERE only slightly more effectively than the binding of ERalpha to ERE. Equol 86-91 estrogen receptor 1 Homo sapiens 181-188 10573180-2 1999 The present study reports the inhibitory effects of six flavonoids, quercetin, genistein, daidzein, equol, (+)-catechin and flavone, on sulphation of p-nitrophenol, a model substrate for the P-form of PST (thermostable, TS) and dopamine, a model substrate for the M-form of PST (thermolabile, TL). Equol 100-105 sulfotransferase family 1A member 1 Homo sapiens 201-204 10942316-3 2000 Genistein and equol, administered by gavage for 4 consecutive days [post-natal day (PND) 17-20, 100 mg/kg body weight], was found to significantly increase uterine weights and the overall uterine concentration of estrogen receptor alpha (ERalpha). Equol 14-19 estrogen receptor 1 (alpha) Mus musculus 213-236 10942316-3 2000 Genistein and equol, administered by gavage for 4 consecutive days [post-natal day (PND) 17-20, 100 mg/kg body weight], was found to significantly increase uterine weights and the overall uterine concentration of estrogen receptor alpha (ERalpha). Equol 14-19 estrogen receptor 1 (alpha) Mus musculus 238-245 10424789-13 1999 Equol and coumestrol decreased K-ras expression in the female tumor cell line. Equol 0-5 KRAS proto-oncogene, GTPase Homo sapiens 31-36 10573180-2 1999 The present study reports the inhibitory effects of six flavonoids, quercetin, genistein, daidzein, equol, (+)-catechin and flavone, on sulphation of p-nitrophenol, a model substrate for the P-form of PST (thermostable, TS) and dopamine, a model substrate for the M-form of PST (thermolabile, TL). Equol 100-105 sulfotransferase family 1A member 1 Homo sapiens 274-277 9103275-2 1997 The soya bean is a rich source of the isoflavonic phyto-oestrogens, daidzein, genistein and equol, compounds which may be cancer-protective in Asian populations. Equol 92-97 brain expressed associated with NEDD4 1 Homo sapiens 9-13 9662412-0 1998 Inhibition of mouse and human CYP 1A- and 2E1-dependent substrate metabolism by the isoflavonoids genistein and equol. Equol 112-117 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 30-45 9662412-2 1998 Genistein and equol inhibited the high capacity component of p-nitrophenol (CYP2E1 substrate) metabolism in liver microsomes from acetone-induced mice with IC50 values of approximately 10 mM and 560 microM, respectively (cf. Equol 14-19 cytochrome P450, family 2, subfamily e, polypeptide 1 Mus musculus 76-82 33034801-8 2021 RESULTS: Equol showed bi-phasic protumor and antitumor effects; at a low concentration, it promoted the tumor growth in hormone receptor-positive cell lines, whereas antitumor effects were generally observed when an excessive amount of dose unexpected in the blood and the tissue was administered. Equol 9-14 nuclear receptor subfamily 4 group A member 1 Homo sapiens 120-136 8594308-1 1996 The interactions of human Sex steroid binding protein (SBP) and the lignans [Nordihydrogaiaretic acid (NDGA) enterolactone (Ent), enterodiol (End)] and isoflavonoid phytoestrogens [Equol (Eq), diazein Dad), genistein (Gen)] were studied. Equol 181-186 selenium binding protein 1 Homo sapiens 55-58 8594308-1 1996 The interactions of human Sex steroid binding protein (SBP) and the lignans [Nordihydrogaiaretic acid (NDGA) enterolactone (Ent), enterodiol (End)] and isoflavonoid phytoestrogens [Equol (Eq), diazein Dad), genistein (Gen)] were studied. Equol 181-183 selenium binding protein 1 Homo sapiens 55-58 1716990-2 1991 They had differential inhibitory effects (NDGA greater than equol greater than enterolactone greater than enterodiol) on the binding of estrone and estradiol to rat AFP and the binding of unsaturated fatty acid to both rat and human AFP. Equol 60-65 alpha-fetoprotein Rattus norvegicus 165-168 34801689-0 2022 Soy isoflavone metabolite equol inhibits cancer cell proliferation in a PAP associated domain containing 5-dependent and an estrogen receptor-independent manner. Equol 26-31 terminal nucleotidyltransferase 4B Homo sapiens 72-106 34801689-4 2022 We aimed to elucidate the mechanism for ER-independent actions of equol. Equol 66-71 estrogen receptor 1 Homo sapiens 40-42 34801689-9 2022 Equol has been found to induce polyadenylation of snoRNAs in a PAPD5-depdendent manner. Equol 0-5 terminal nucleotidyltransferase 4B Homo sapiens 63-68 34801689-11 2022 Together, these results suggest that equol may have a dual effect on ER-positive cancer cells, acting with, antiproliferative activity through PAPD5 and exhibiting proliferative activity via ERalpha and the former could be associated with miR-320a. Equol 37-42 terminal nucleotidyltransferase 4B Homo sapiens 143-148 34801689-11 2022 Together, these results suggest that equol may have a dual effect on ER-positive cancer cells, acting with, antiproliferative activity through PAPD5 and exhibiting proliferative activity via ERalpha and the former could be associated with miR-320a. Equol 37-42 estrogen receptor 1 Homo sapiens 191-198 34801689-11 2022 Together, these results suggest that equol may have a dual effect on ER-positive cancer cells, acting with, antiproliferative activity through PAPD5 and exhibiting proliferative activity via ERalpha and the former could be associated with miR-320a. Equol 37-42 microRNA 320a Homo sapiens 239-247 34681876-5 2021 Finally, a brief history of cosmetics to nutraceuticals is covered plus the characteristics of phytoestrogens, resveratrol and equol on: (g) estrogen receptor binding, (h) topical and oral dosing, and (i) in vitro, molecular mechanisms and select clinical evidence, where both phytoestrogens (resveratrol and equol) demonstrate promising applications to improve skin health is presented along with future directions of nutraceuticals. Equol 127-132 estrogen receptor 1 Homo sapiens 141-158 34502054-0 2021 The Oxidation of Equol by Tyrosinase Produces a Unique Di-ortho-Quinone: Possible Implications for Melanocyte Toxicity. Equol 17-22 tyrosinase Homo sapiens 26-36 34749871-11 2021 CONCLUSION: Equol could reduce female LDLR KO hamster blood lipid. Equol 12-17 low density lipoprotein receptor Homo sapiens 38-42 34088932-2 2021 S-Equol (SE), a selective estrogen receptor beta agonist, has been implicated as a neuroprotective and/or neurorestorative therapeutic for HIV-1 associated neurocognitive disorders (HAND); its therapeutic utility for motivational alterations, however, has yet to be systematically evaluated. Equol 0-7 estrogen receptor 1 Homo sapiens 26-48 34209006-0 2021 S-Equol Protects Chondrocytes against Sodium Nitroprusside-Caused Matrix Loss and Apoptosis through Activating PI3K/Akt Pathway. Equol 0-7 AKT serine/threonine kinase 1 Homo sapiens 116-119 34209006-7 2021 Moreover, S-Equol activates the PI3K/Akt pathway, which is an upstream regulation of p53 and NO production and is associated with apoptosis and matrix degradation. Equol 10-17 AKT serine/threonine kinase 1 Homo sapiens 37-40 34209006-7 2021 Moreover, S-Equol activates the PI3K/Akt pathway, which is an upstream regulation of p53 and NO production and is associated with apoptosis and matrix degradation. Equol 10-17 tumor protein p53 Homo sapiens 85-88 34209006-8 2021 As a pretreatment of phosphoinositide 3-kinases (PI3K) inhibitor, all S-Equol protective functions against SNP decrease or disappear. Equol 70-77 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 21-47 34209006-9 2021 In conclusion, through PI3K/Akt activation, S-Equol can protect chondrocytes against SNP-induced matrix degradation and apoptosis, which are commonly found in OA, suggesting S-Equol is a potential for OA prevention. Equol 44-51 AKT serine/threonine kinase 1 Homo sapiens 28-31 34157864-9 2021 The protective effects of daidzein and equol required estrogen receptor-beta. Equol 39-44 estrogen receptor 1 (alpha) Mus musculus 54-76 34157864-12 2021 CONCLUSIONS: Our study establishes that both dietary daidzein and its metabolite, equol, protect against aneurysm formation in ovariectomized female mice through the activation of estrogen receptor-beta and subsequent suppression of inflammation. Equol 82-87 estrogen receptor 1 (alpha) Mus musculus 180-202 34088932-2 2021 S-Equol (SE), a selective estrogen receptor beta agonist, has been implicated as a neuroprotective and/or neurorestorative therapeutic for HIV-1 associated neurocognitive disorders (HAND); its therapeutic utility for motivational alterations, however, has yet to be systematically evaluated. Equol 9-11 estrogen receptor 1 Homo sapiens 26-48 35563633-0 2022 Soy-Derived Equol Induces Antioxidant Activity in Zebrafish in an Nrf2-Independent Manner. Equol 12-17 nfe2 like bZIP transcription factor 2a Danio rerio 66-70 35563633-5 2022 The antioxidant effect of equol was also shown in Nrf2-mutant zebrafish nfe2l2afh318, suggesting that this effect was not mediated by the Keap1-Nrf2 pathway. Equol 26-31 nfe2 like bZIP transcription factor 2a Danio rerio 50-54 35563633-5 2022 The antioxidant effect of equol was also shown in Nrf2-mutant zebrafish nfe2l2afh318, suggesting that this effect was not mediated by the Keap1-Nrf2 pathway. Equol 26-31 nuclear factor, erythroid 2 Danio rerio 72-76 35563633-7 2022 Because nfe2l2afh318 is an amino acid-substitution mutant (Arg485Lue), we considered that the antioxidant effect of equol in this mutant might be due to residual Nrf2 activity. Equol 116-121 nfe2 like bZIP transcription factor 2a Danio rerio 162-166 35563633-9 2022 As a result, equol showed strong antioxidant effects even in Nrf2-knockout larvae, suggesting that equol indeed upregulates antioxidant activity in zebrafish in an Nrf2-independent manner. Equol 13-18 nfe2 like bZIP transcription factor 2a Danio rerio 61-65 35563633-9 2022 As a result, equol showed strong antioxidant effects even in Nrf2-knockout larvae, suggesting that equol indeed upregulates antioxidant activity in zebrafish in an Nrf2-independent manner. Equol 13-18 nfe2 like bZIP transcription factor 2a Danio rerio 164-168 35563633-9 2022 As a result, equol showed strong antioxidant effects even in Nrf2-knockout larvae, suggesting that equol indeed upregulates antioxidant activity in zebrafish in an Nrf2-independent manner. Equol 99-104 nfe2 like bZIP transcription factor 2a Danio rerio 164-168 33709111-11 2021 CONCLUSIONS: Serum isoflavones and equol exposure were associated with reduced cIMT progression, mediated by SHBG and SBP. Equol 35-40 sex hormone binding globulin Homo sapiens 109-113 34038497-7 2021 In addition, S-equol administration significantly decreased the levels of pro-inflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin-10, interleukin-1beta), increased the levels of 5-hydroxytryptamine and norepinephrine, and normalized the release of tryptophan and kynurenine in the hippocampi of lipopolysaccharide-treated mice. Equol 13-20 tumor necrosis factor Mus musculus 102-123 34038497-7 2021 In addition, S-equol administration significantly decreased the levels of pro-inflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin-10, interleukin-1beta), increased the levels of 5-hydroxytryptamine and norepinephrine, and normalized the release of tryptophan and kynurenine in the hippocampi of lipopolysaccharide-treated mice. Equol 13-20 interleukin 6 Mus musculus 125-138 34038497-7 2021 In addition, S-equol administration significantly decreased the levels of pro-inflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin-10, interleukin-1beta), increased the levels of 5-hydroxytryptamine and norepinephrine, and normalized the release of tryptophan and kynurenine in the hippocampi of lipopolysaccharide-treated mice. Equol 13-20 interleukin 10 Mus musculus 140-154 34038497-7 2021 In addition, S-equol administration significantly decreased the levels of pro-inflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin-10, interleukin-1beta), increased the levels of 5-hydroxytryptamine and norepinephrine, and normalized the release of tryptophan and kynurenine in the hippocampi of lipopolysaccharide-treated mice. Equol 13-20 interleukin 1 beta Mus musculus 156-173 34038497-9 2021 These findings demonstrated that S-equol significantly alleviated the depressive-like behavior induced by acute systemic injection of LPS, and its antidepressant action was related to mediation of neuroinflammation via the TLR4/NF-kappaB signaling pathway, normalization of the monoamine neurotransmitter levels, reversal of tryptophan metabolism dysfunction, and enhancement of synaptic plasticity. Equol 33-40 toll-like receptor 4 Mus musculus 223-227 34038497-9 2021 These findings demonstrated that S-equol significantly alleviated the depressive-like behavior induced by acute systemic injection of LPS, and its antidepressant action was related to mediation of neuroinflammation via the TLR4/NF-kappaB signaling pathway, normalization of the monoamine neurotransmitter levels, reversal of tryptophan metabolism dysfunction, and enhancement of synaptic plasticity. Equol 33-40 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 228-237 31858373-2 2020 Selective estrogen receptor beta agonists, including S-Equol (SE), have been implicated as potential therapeutic targets for the treatment of neurocognitive disorders. Equol 53-60 estrogen receptor 2 Homo sapiens 10-32 33462142-10 2021 Lastly, the ERbeta-selective agonist S-equol was evaluated for its efficacy to boost immune checkpoint blockade (ICB)-based anticancer immunotherapy.Disabling the ERbeta-specific phosphotyrosine switch in tumor-bearing hosts exacerbates tumor growth. Equol 37-44 estrogen receptor 1 (alpha) Mus musculus 12-18 33462142-10 2021 Lastly, the ERbeta-selective agonist S-equol was evaluated for its efficacy to boost immune checkpoint blockade (ICB)-based anticancer immunotherapy.Disabling the ERbeta-specific phosphotyrosine switch in tumor-bearing hosts exacerbates tumor growth. Equol 37-44 estrogen receptor 1 (alpha) Mus musculus 163-169 33462142-13 2021 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol 0-7 estrogen receptor 1 (alpha) Mus musculus 55-61 33462142-13 2021 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol 0-7 programmed cell death 1 Mus musculus 101-105 33462142-13 2021 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol 0-7 programmed cell death 1 Mus musculus 107-138 33462142-13 2021 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol 0-7 estrogen receptor 1 (alpha) Mus musculus 217-223 33462142-13 2021 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol 0-7 estrogen receptor 1 (alpha) Mus musculus 217-223 33462142-14 2021 Our findings support the development of ERbeta agonists including S-equol in combination with ICB immunotherapy for cancer treatment. Equol 66-73 estrogen receptor 1 (alpha) Mus musculus 40-46 32705888-5 2021 In contrast, Src activation conferred resistance to either daidzein, glycitein or equol, but rendered the cells more sensitive to genistein, compared to HAG/neo3-5 cells. Equol 82-87 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 13-16 32572977-5 2020 Equol inhibited the expression of SREBPC1 gene by inhibiting SHP in the liver via transcription factor FXR, thereby inhibiting the synthesis of triglyceride and fatty acid in the liver. Equol 0-5 nuclear receptor subfamily 0, group B, member 2 Rattus norvegicus 61-64 32572977-5 2020 Equol inhibited the expression of SREBPC1 gene by inhibiting SHP in the liver via transcription factor FXR, thereby inhibiting the synthesis of triglyceride and fatty acid in the liver. Equol 0-5 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 103-106 31858373-2 2020 Selective estrogen receptor beta agonists, including S-Equol (SE), have been implicated as potential therapeutic targets for the treatment of neurocognitive disorders. Equol 62-64 estrogen receptor 2 Homo sapiens 10-32 31623342-9 2019 Treatment with the ER antagonist, ICI-182,780 (1 muM), completely blocked the effects of S-equol and 17beta-estradiol on cell viability, ERalpha, and ERK1/2 after Abeta (25-35) exposure. Equol 89-96 mitogen-activated protein kinase 3 Homo sapiens 150-156 32492805-4 2020 Equol is one of the most active isoflavone metabolites, produced by intestinal bacteria, and acts as a selective estrogen receptor modulator. Equol 0-5 estrogen receptor 1 Homo sapiens 113-130 31956333-0 2020 S-Equol ameliorates insulin secretion failure through Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 0-7 MLX interacting protein-like Rattus norvegicus 54-60 31956333-0 2020 S-Equol ameliorates insulin secretion failure through Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 0-7 thioredoxin interacting protein Rattus norvegicus 61-66 31956333-0 2020 S-Equol ameliorates insulin secretion failure through Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 0-7 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 92-95 31956333-7 2020 The dual luciferase reporter assay, chromatin immunoprecipitation assay and Western-blotting followed by Chrebp small interfering RNAs were utilized to clarify the mechanism of transcriptional regulation of S-Equol on Chrebp/Txnip signaling and the activities of protein kinase A (PKA) and protein phophatase (PP2A) were also detected. Equol 207-214 MLX interacting protein-like Rattus norvegicus 105-111 31956333-7 2020 The dual luciferase reporter assay, chromatin immunoprecipitation assay and Western-blotting followed by Chrebp small interfering RNAs were utilized to clarify the mechanism of transcriptional regulation of S-Equol on Chrebp/Txnip signaling and the activities of protein kinase A (PKA) and protein phophatase (PP2A) were also detected. Equol 207-214 MLX interacting protein-like Rattus norvegicus 218-224 31956333-7 2020 The dual luciferase reporter assay, chromatin immunoprecipitation assay and Western-blotting followed by Chrebp small interfering RNAs were utilized to clarify the mechanism of transcriptional regulation of S-Equol on Chrebp/Txnip signaling and the activities of protein kinase A (PKA) and protein phophatase (PP2A) were also detected. Equol 207-214 thioredoxin interacting protein Rattus norvegicus 225-230 31956333-7 2020 The dual luciferase reporter assay, chromatin immunoprecipitation assay and Western-blotting followed by Chrebp small interfering RNAs were utilized to clarify the mechanism of transcriptional regulation of S-Equol on Chrebp/Txnip signaling and the activities of protein kinase A (PKA) and protein phophatase (PP2A) were also detected. Equol 207-214 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 263-279 31956333-7 2020 The dual luciferase reporter assay, chromatin immunoprecipitation assay and Western-blotting followed by Chrebp small interfering RNAs were utilized to clarify the mechanism of transcriptional regulation of S-Equol on Chrebp/Txnip signaling and the activities of protein kinase A (PKA) and protein phophatase (PP2A) were also detected. Equol 207-214 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 281-284 31956333-8 2020 Results: In vivo, Equol supplementation delayed the onset of the hyperglycemia and hyperlipemia, ameliorated insulin secretion failure, enhanced GSIS in isolated islets, and significantly reduced Chrebp and Txnip expression in islets. Equol 18-23 MLX interacting protein-like Rattus norvegicus 196-202 31956333-8 2020 Results: In vivo, Equol supplementation delayed the onset of the hyperglycemia and hyperlipemia, ameliorated insulin secretion failure, enhanced GSIS in isolated islets, and significantly reduced Chrebp and Txnip expression in islets. Equol 18-23 thioredoxin interacting protein Rattus norvegicus 207-212 31956333-10 2020 Moreover, S-Equol dramatically suppressed Txnip transcription, as evident by the reduction of Txnip protein and mRNA levels and decrease in the Txnip promoter-driven luciferase activity. Equol 10-17 thioredoxin interacting protein Rattus norvegicus 42-47 31956333-10 2020 Moreover, S-Equol dramatically suppressed Txnip transcription, as evident by the reduction of Txnip protein and mRNA levels and decrease in the Txnip promoter-driven luciferase activity. Equol 10-17 thioredoxin interacting protein Rattus norvegicus 94-99 31956333-10 2020 Moreover, S-Equol dramatically suppressed Txnip transcription, as evident by the reduction of Txnip protein and mRNA levels and decrease in the Txnip promoter-driven luciferase activity. Equol 10-17 thioredoxin interacting protein Rattus norvegicus 94-99 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 11-18 MLX interacting protein-like Rattus norvegicus 43-49 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 11-18 MAX dimerization protein MLX Rattus norvegicus 50-53 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 11-18 MLX interacting protein-like Rattus norvegicus 92-98 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 11-18 thioredoxin interacting protein Rattus norvegicus 106-111 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 11-18 MLX interacting protein-like Rattus norvegicus 92-98 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 13-18 MLX interacting protein-like Rattus norvegicus 43-49 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 13-18 MAX dimerization protein MLX Rattus norvegicus 50-53 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 13-18 MLX interacting protein-like Rattus norvegicus 92-98 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 13-18 thioredoxin interacting protein Rattus norvegicus 106-111 31956333-11 2020 Meanwhile, S-Equol significantly inhibited Chrebp/Mlx expression and decreased occupancy of Chrebp on the Txnip promoter, and combined with siChrebp, we confirmed that S-Equol improvement of insulin secretion was partially through the Chrebp/Txnip pathway. Equol 13-18 MLX interacting protein-like Rattus norvegicus 92-98 31956333-12 2020 Furthermore, S-Equol significantly decrease nuclear translocation of Chrebp, which was related with the decrease activity of protein kinase A (PKA) and the increase activity of protein phophatase (PP2A). Equol 13-20 MLX interacting protein-like Rattus norvegicus 69-75 31956333-12 2020 Furthermore, S-Equol significantly decrease nuclear translocation of Chrebp, which was related with the decrease activity of protein kinase A (PKA) and the increase activity of protein phophatase (PP2A). Equol 13-20 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 125-141 31956333-12 2020 Furthermore, S-Equol significantly decrease nuclear translocation of Chrebp, which was related with the decrease activity of protein kinase A (PKA) and the increase activity of protein phophatase (PP2A). Equol 13-20 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 143-146 31956333-13 2020 Conclusions: S-Equol could ameliorate insulin secretion failure, which was dependent on the suppression of Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 13-20 MLX interacting protein-like Rattus norvegicus 107-113 31956333-13 2020 Conclusions: S-Equol could ameliorate insulin secretion failure, which was dependent on the suppression of Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 13-20 thioredoxin interacting protein Rattus norvegicus 114-119 31956333-13 2020 Conclusions: S-Equol could ameliorate insulin secretion failure, which was dependent on the suppression of Chrebp/Txnip signaling via modulating PKA/PP2A activities. Equol 13-20 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 145-148 31567873-1 2020 OBJECTIVE: PhytoSERM is a selective estrogen receptor beta (ERbeta) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. Equol 138-145 estrogen receptor 2 Homo sapiens 36-58 31567873-1 2020 OBJECTIVE: PhytoSERM is a selective estrogen receptor beta (ERbeta) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. Equol 138-145 estrogen receptor 2 Homo sapiens 60-66 31748434-11 2020 A path analysis indicated that these associations of equol with androgens in postmenopausal women might be mediated by SHBG. Equol 53-58 sex hormone binding globulin Homo sapiens 119-123 31635400-0 2019 A Novel Mechanism of S-equol Action in Neurons and Astrocytes: The Possible Involvement of GPR30/GPER1. Equol 21-28 G protein-coupled estrogen receptor 1 Mus musculus 91-96 31635400-0 2019 A Novel Mechanism of S-equol Action in Neurons and Astrocytes: The Possible Involvement of GPR30/GPER1. Equol 21-28 G protein-coupled estrogen receptor 1 Mus musculus 97-102 31635400-7 2019 On the other hand, in astrocytes, S-equol induced cell proliferation and cell migration with an increase in the phosphorylated extracellular-signal-regulated kinase 1/2 and F-actin rearrangements. Equol 34-41 mitogen-activated protein kinase 3 Mus musculus 127-174 31635400-9 2019 These findings indicated that S-equol may enhanced cerebellar development by affecting both neurons and astrocytes through several signaling pathways, including GPR30 and ERs. Equol 30-37 G protein-coupled estrogen receptor 1 Mus musculus 161-166 31623342-0 2019 Equol Pretreatment Protection of SH-SY5Y Cells against Abeta (25-35)-Induced Cytotoxicity and Cell-Cycle Reentry via Sustaining Estrogen Receptor Alpha Expression. Equol 0-5 estrogen receptor 1 Homo sapiens 128-151 31623342-4 2019 This study investigated the possible mechanism of the neuron cell-protecting effect of equol during treatment with Abeta. Equol 87-92 amyloid beta precursor protein Homo sapiens 115-120 31623342-9 2019 Treatment with the ER antagonist, ICI-182,780 (1 muM), completely blocked the effects of S-equol and 17beta-estradiol on cell viability, ERalpha, and ERK1/2 after Abeta (25-35) exposure. Equol 89-96 estrogen receptor 1 Homo sapiens 137-144 31390527-0 2019 S-equol inhibits proliferation and promotes apoptosis of human breast cancer MCF-7 cells via regulating miR-10a-5p and PI3K/AKT pathway. Equol 0-7 microRNA 10a Homo sapiens 104-111 31390527-0 2019 S-equol inhibits proliferation and promotes apoptosis of human breast cancer MCF-7 cells via regulating miR-10a-5p and PI3K/AKT pathway. Equol 0-7 AKT serine/threonine kinase 1 Homo sapiens 124-127 31390527-10 2019 It was further found that S-equol exerts an anti-breast cancer effect by up-regulating miR-10a-5p and inhibiting the PI3K/AKT pathway. Equol 26-33 microRNA 10a Homo sapiens 87-94 31390527-10 2019 It was further found that S-equol exerts an anti-breast cancer effect by up-regulating miR-10a-5p and inhibiting the PI3K/AKT pathway. Equol 26-33 AKT serine/threonine kinase 1 Homo sapiens 122-125 31390527-11 2019 Our study revealed the mechanism of S-equol against breast cancer, and miR-10a-5p may be a potential target for the treatment of breast cancer. Equol 36-43 microRNA 10a Homo sapiens 71-78 31623342-9 2019 Treatment with the ER antagonist, ICI-182,780 (1 muM), completely blocked the effects of S-equol and 17beta-estradiol on cell viability, ERalpha, and ERK1/2 after Abeta (25-35) exposure. Equol 89-96 amyloid beta precursor protein Homo sapiens 163-168 31623342-10 2019 These data suggest that S-equol possesses a neuroprotective potential as it effectively antagonizes Abeta (25-35)-induced cell cytotoxicity and prevents cell cycle reentry in SH-SY5Y cells. Equol 24-31 amyloid beta precursor protein Homo sapiens 100-105 31623342-11 2019 The mechanism underlying S-equol neuroprotection might involve ERalpha-mediated pathways. Equol 25-32 estrogen receptor 1 Homo sapiens 63-70 31163218-1 2019 S-equol, an active metabolite of the soy isoflavone daidzein, is mainly metabolized into glucuronide(s) by UDP-glucuronosyltransferase (UGT) enzymes in mammals. Equol 0-7 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 107-134 31163218-1 2019 S-equol, an active metabolite of the soy isoflavone daidzein, is mainly metabolized into glucuronide(s) by UDP-glucuronosyltransferase (UGT) enzymes in mammals. Equol 0-7 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 136-139 30889096-1 2019 OBJECTIVE: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-beta (ERbeta); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity. Equol 66-73 estrogen receptor 1 Homo sapiens 117-139 30889096-1 2019 OBJECTIVE: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-beta (ERbeta); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity. Equol 66-73 estrogen receptor 1 Homo sapiens 141-147 29692883-0 2018 S-Equol, a Major Isoflavone from Soybean, Inhibits Nitric Oxide Production in Lipopolysaccharide-Stimulated Rat Astrocytes Partially via the GPR30-Mediated Pathway. Equol 0-7 G protein-coupled estrogen receptor 1 Rattus norvegicus 141-146 30911044-6 2019 However, pre-treatment of PBMCs with physiologically-relevant concentrations of genistein (p = 0.0023) and equol (p = 0.006) decreases interleukin (IL)-12/IL-18-induced interferon-gamma (IFN-gamma) production versus controls. Equol 107-112 interleukin 18 Mus musculus 155-160 30911044-6 2019 However, pre-treatment of PBMCs with physiologically-relevant concentrations of genistein (p = 0.0023) and equol (p = 0.006) decreases interleukin (IL)-12/IL-18-induced interferon-gamma (IFN-gamma) production versus controls. Equol 107-112 interferon gamma Homo sapiens 169-185 30911044-6 2019 However, pre-treatment of PBMCs with physiologically-relevant concentrations of genistein (p = 0.0023) and equol (p = 0.006) decreases interleukin (IL)-12/IL-18-induced interferon-gamma (IFN-gamma) production versus controls. Equol 107-112 interferon gamma Homo sapiens 187-196 29101532-0 2019 The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect. Equol 32-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 67-71 29101532-0 2019 The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect. Equol 32-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 72-77 29934673-6 2018 The study showed that aglycones of soy isoflavones and the main biologically active metabolite S-equol were able to significantly inhibit hOATP2B1-mediated transport. Equol 95-102 solute carrier organic anion transporter family member 2B1 Homo sapiens 138-146 28877739-9 2017 The ERbeta selective agonist DPN and low physiological concentrations of the soy-derived phytoestrogens genistein, daidzein, and s-equol also decreased sensitivity of D283 Med cells to cisplatin. Equol 129-136 estrogen receptor 2 Homo sapiens 4-10 28926513-1 2018 OBJECTIVE: Selected estrogen receptor beta-selective phytoestrogen (phytoSERM), a preparation of genistein, daidzein, and S-equol, has an 83-fold selective affinity for estrogen receptor (ER) beta, and may promote neuronal survival and estrogenic mechanisms in the brain without exerting feminizing activity in the periphery. Equol 122-129 estrogen receptor 2 Homo sapiens 20-42 28926513-1 2018 OBJECTIVE: Selected estrogen receptor beta-selective phytoestrogen (phytoSERM), a preparation of genistein, daidzein, and S-equol, has an 83-fold selective affinity for estrogen receptor (ER) beta, and may promote neuronal survival and estrogenic mechanisms in the brain without exerting feminizing activity in the periphery. Equol 122-129 estrogen receptor 2 Homo sapiens 169-196 27907038-0 2016 Equol Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice by Inhibiting Endoplasmic Reticulum Stress via Activation of Nrf2 in Endothelial Cells. Equol 0-5 apolipoprotein E Mus musculus 36-52 28264445-7 2017 Additionally, Equol protects neurons from neuroinflammatory injury mediated by LPS-activated microglia through downregulation of neuronal apoptosis, increased neurite outgrowth in N2a cell and neurotrophins like nerve growth factor (NGF) production through astrocytes further supporting its neuroprotective potential. Equol 14-19 toll-like receptor 4 Mus musculus 79-82 28598847-3 2017 To assess whether an ERbeta agonist could improve mitochondrial function in actual AD subjects, we administered S-equol (10 mg twice daily) to 15 women with AD and determined the platelet mitochondria cytochrome oxidase (COX) activity before initiating S-equol (lead-in), after two weeks of S-equol (active treatment), and two weeks after stopping S-equol (wash-out). Equol 112-119 estrogen receptor 1 Homo sapiens 21-27 28985044-8 2017 Although (S)-equol favors binding to human estrogen receptor (hER) beta over hERalpha, (-)-5-hydroxy-equol showed the opposite preference. Equol 9-18 estrogen receptor 1 Homo sapiens 43-85 28264445-5 2017 Effects of Equol on the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX-2), Mitogen activated protein kinase (MAPK) signaling proteins, and apoptosis-related proteins were measured by western blot analysis. Equol 11-16 nitric oxide synthase 2, inducible Mus musculus 38-69 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 toll-like receptor 4 Mus musculus 40-43 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 toll-like receptor 4 Mus musculus 53-57 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 tumor necrosis factor Mus musculus 226-253 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 tumor necrosis factor Mus musculus 255-264 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 interleukin 6 Mus musculus 270-283 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 interleukin 6 Mus musculus 285-289 28264445-6 2017 Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells. Equol 0-5 toll-like receptor 4 Mus musculus 315-318 27907038-0 2016 Equol Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice by Inhibiting Endoplasmic Reticulum Stress via Activation of Nrf2 in Endothelial Cells. Equol 0-5 nuclear factor, erythroid derived 2, like 2 Mus musculus 129-133 27907038-8 2016 Furthermore, equol treatment attenuated palmitate, t-BHP or thapsigargin-induced upregulation of ER stress markers, including p-PERK, p-eIF2alpha, GRP78, ATF6 and CHOP proteins expression. Equol 13-18 eukaryotic translation initiation factor 2 alpha kinase 3 Mus musculus 128-132 27907038-8 2016 Furthermore, equol treatment attenuated palmitate, t-BHP or thapsigargin-induced upregulation of ER stress markers, including p-PERK, p-eIF2alpha, GRP78, ATF6 and CHOP proteins expression. Equol 13-18 heat shock protein 5 Mus musculus 147-152 27907038-8 2016 Furthermore, equol treatment attenuated palmitate, t-BHP or thapsigargin-induced upregulation of ER stress markers, including p-PERK, p-eIF2alpha, GRP78, ATF6 and CHOP proteins expression. Equol 13-18 activating transcription factor 6 Mus musculus 154-158 27907038-8 2016 Furthermore, equol treatment attenuated palmitate, t-BHP or thapsigargin-induced upregulation of ER stress markers, including p-PERK, p-eIF2alpha, GRP78, ATF6 and CHOP proteins expression. Equol 13-18 DNA-damage inducible transcript 3 Mus musculus 163-167 26638886-0 2016 S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway. Equol 0-7 AKT serine/threonine kinase 1 Homo sapiens 151-154 27802587-7 2016 Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis. Equol 38-43 mitogen-activated protein kinase kinase 7 Homo sapiens 156-159 27802587-7 2016 Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis. Equol 38-43 mitogen-activated protein kinase 1 Homo sapiens 140-143 27323858-5 2016 Furthermore, ERbeta-specific agonists such as S-equol enhance ERbeta phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERbeta activation. Equol 46-53 estrogen receptor 2 Homo sapiens 13-19 27323858-5 2016 Furthermore, ERbeta-specific agonists such as S-equol enhance ERbeta phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERbeta activation. Equol 46-53 estrogen receptor 2 Homo sapiens 62-68 27323858-5 2016 Furthermore, ERbeta-specific agonists such as S-equol enhance ERbeta phosphorylation, suggesting a crosstalk between ligand- and posttranslational modification-dependent ERbeta activation. Equol 46-53 estrogen receptor 2 Homo sapiens 62-68 27088761-8 2016 Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Equol 44-49 S-phase kinase associated protein 2 Homo sapiens 174-178 27088761-8 2016 Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Equol 44-49 androgen receptor Homo sapiens 188-205 27088761-8 2016 Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Equol 159-164 S-phase kinase associated protein 2 Homo sapiens 174-178 27088761-8 2016 Taken together, soy isoflavones, especially equol, appear to be promising as chemopreventive and therapeutic agents for prostate cancer based on the fact that equol augments Skp2-mediated androgen receptor degradation. Equol 159-164 androgen receptor Homo sapiens 188-205 27027338-0 2016 Relative Inhibitions of 5-Lipoxygenase and Myeloperoxidase and Free-Radical Scavenging Activities of Daidzein, Dihydrodaidzein, and Equol. Equol 132-137 arachidonate 5-lipoxygenase Homo sapiens 24-38 27027338-0 2016 Relative Inhibitions of 5-Lipoxygenase and Myeloperoxidase and Free-Radical Scavenging Activities of Daidzein, Dihydrodaidzein, and Equol. Equol 132-137 myeloperoxidase Homo sapiens 43-58 27027338-4 2016 Daidzein, dihydrodaidzein, and equol did not affect the enzymatic hydrolysis of leukotriene A4 to leukotriene B4, suggesting that they exerted their inhibitory effects on the 5-lipoxygenase activity. Equol 31-36 arachidonate 5-lipoxygenase Homo sapiens 175-189 27802587-0 2016 Equol Induces Mitochondria-Dependent Apoptosis in Human Gastric Cancer Cells via the Sustained Activation of ERK1/2 Pathway. Equol 0-5 mitogen-activated protein kinase 3 Homo sapiens 109-115 27802587-7 2016 Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis. Equol 38-43 mitogen-activated protein kinase 1 Homo sapiens 80-117 27802587-7 2016 Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis. Equol 38-43 mitogen-activated protein kinase 1 Homo sapiens 119-122 27802587-7 2016 Moreover, treating MGC-803 cells with equol induced the sustained activation of extracellular signal-regulated kinase (ERK), and inhibiting ERK by U0126, a MEK/ERK pathway inhibitor, significantly attenuated the equol-induced cell apoptosis. Equol 38-43 mitogen-activated protein kinase 1 Homo sapiens 140-143 27088761-0 2016 Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Equol 0-5 androgen receptor Homo sapiens 61-78 27088761-0 2016 Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Equol 0-5 S-phase kinase associated protein 2 Homo sapiens 82-117 27088761-4 2016 Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. Equol 23-28 androgen receptor Homo sapiens 40-57 26638886-0 2016 S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway. Equol 0-7 forkhead box O3 Homo sapiens 155-161 26638886-3 2016 We herein investigated the inhibitory effects of S-equol, an isoflavandiol metabolized from daidzein by bacterial flora in the intestines, on the LnCaP, DU145 and PC3 human prostate cancer cell lines. Equol 49-56 chromobox 8 Homo sapiens 163-166 26638886-9 2016 Moreover, treatment with S-equol inhibited the growth of PC3 xenograft tumors in BALB/c nude mice. Equol 25-32 chromobox 8 Mus musculus 57-60 26806730-8 2016 CONCLUSION: Equol confers neuroprotection against hypoxia/reoxygenation injury in PC12 cells by inhibiting the generation of ROS very likely as a result of down-regulation of gp91(phox) and inhibition of Src phosphorylation. Equol 12-17 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 204-207 24368316-6 2014 S-equol binds selectively to ERbeta with an affinity similar to that of genistein but has low transcriptional potency. Equol 0-7 estrogen receptor 2 Rattus norvegicus 29-35 25593313-0 2015 Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G. Equol 0-5 MYC proto-oncogene, bHLH transcription factor Homo sapiens 102-107 25593313-0 2015 Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G. Equol 0-5 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 112-117 25593313-3 2015 We previously reported that equol, a metabolite of the soy isoflavone daidzein, may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI). Equol 28-33 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 175-181 25593313-4 2015 In estrogen receptor negative (ER-) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were associated with increased cell viability and the selective translation of mRNAs that use non-canonical means of initiation, including internal ribosome entry site (IRES), ribosome shunting, and eIF4G enhancers. Equol 68-73 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 101-106 25593313-4 2015 In estrogen receptor negative (ER-) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were associated with increased cell viability and the selective translation of mRNAs that use non-canonical means of initiation, including internal ribosome entry site (IRES), ribosome shunting, and eIF4G enhancers. Equol 68-73 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 313-318 25198009-6 2014 Western blot analysis revealed that protein levels of gp91(phox) and phosphorylated Src-Tyr416 (p-Src) in ischemic cerebral cortex were increased in rats treated with vehicle, which was reversed in animals treated with equol. Equol 219-224 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 84-87 25198009-6 2014 Western blot analysis revealed that protein levels of gp91(phox) and phosphorylated Src-Tyr416 (p-Src) in ischemic cerebral cortex were increased in rats treated with vehicle, which was reversed in animals treated with equol. Equol 219-224 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 98-101 26420965-0 2015 Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway. Equol 0-5 AKT serine/threonine kinase 1 Homo sapiens 77-80 24461312-3 2014 S-(-)equol, a metabolite of the soy isoflavone daidzein, has a higher bioavailability and greater affinity for estrogen receptor beta than daidzein. Equol 0-10 estrogen receptor 2 Homo sapiens 111-133 24260155-12 2013 Notably, the ability of S-(-)equol to protect against H2O2-induced cell apoptosis was attenuated in cells transfected with an siRNA against Nrf2. Equol 24-34 NFE2 like bZIP transcription factor 2 Homo sapiens 140-144 23857583-6 2013 The corepressor activity of Tip60 at the ERE site is abolished by diarylpropionitrile, genistein, equol, and bisphenol A, whereas its coactivation at the AP-1 site is augmented by fulvestrant (ICI 182,780). Equol 98-103 lysine acetyltransferase 5 Homo sapiens 28-33